CGEN vs RXRX

For growth investors, Recursion Pharmaceuticals, Inc.

(RXRX) is the stronger pick with 26. 9% revenue growth year-over-year, versus -16. 7% for Compugen Ltd. (CGEN). Analysts rate Compugen Ltd. (CGEN) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Compugen Ltd.

(CGEN) delivered a total return of -62. 3%, compared to -88. 2% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: CGEN returned -57. 2% versus RXRX's -81. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Compugen Ltd.

(CGEN) is the lower-risk stock at 1. 68β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 89% more volatile than CGEN relative to the S&P 500. On balance sheet safety, Compugen Ltd. (CGEN) carries a lower debt/equity ratio of 5% versus 7% for Recursion Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Recursion Pharmaceuticals, Inc.

(RXRX) is pulling ahead at 26. 9% versus -16. 7% for Compugen Ltd. (CGEN). On earnings-per-share growth, the picture is similar: Compugen Ltd. grew EPS 23. 8% year-over-year, compared to 14. 8% for Recursion Pharmaceuticals, Inc.. Over a 3-year CAGR, CGEN leads at 66. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Compugen Ltd.

(CGEN) is the more profitable company, earning -51. 1% net margin versus -863. 4% for Recursion Pharmaceuticals, Inc. — meaning it keeps -51. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CGEN leads at -53. 4% versus -867. 9% for RXRX. At the gross margin level — before operating expenses — CGEN leads at 71. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Compugen Ltd.

(CGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CGEN: -57. 2%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CGEN is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.